Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q92581

UPID:
SL9A6_HUMAN

ALTERNATIVE NAMES:
Na(+)/H(+) exchanger 6; Solute carrier family 9 member 6

ALTERNATIVE UPACC:
Q92581; A6NIQ9; A8K160; B4DU30; B7ZAE0; Q3ZCW7; Q5JPP8; Q5JPP9; Q86VS0; Q8WYK8

BACKGROUND:
The Solute carrier family 9 member 6, or Sodium/hydrogen exchanger 6, is integral in maintaining cellular homeostasis. It counteracts vacuolar (V)-ATPase-generated acidity, facilitating proton efflux, thereby alkalizing endosomal pH. This function is vital for endosomal cargo recycling, synaptic development, and cell polarity. SLC9A6 also regulates intracellular pH in specialized cells, highlighting its broad physiological impact.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Intellectual developmental disorder, X-linked, syndromic, Christianson type, SLC9A6 presents a promising target for therapeutic intervention. Exploring SLC9A6's function offers a pathway to developing treatments for this and related neurological conditions, emphasizing the importance of further research into its mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.